Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine

Indrani Poddar, Patrick Michael Callahan, Caterina M. Hernandez, Xiangkun Yang, Michael G. Bartlett, Alvin V Terry

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20 years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5 mg/kg/day) or quetiapine (25.0 mg/kg/day) for 30 or 90 days and then an acute injection of vehicle or tropisetron (3.0 mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90 days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90 days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalBiochemical Pharmacology
Volume151
DOIs
StatePublished - May 1 2018

Fingerprint

tropisetron
Risperidone
Antipsychotic Agents
Rats
Object recognition
Data storage equipment
Schizophrenia
Nicotinic Receptors
Cognition
Animals
Pharmaceutical Preparations
Therapeutics
Quetiapine Fumarate
Recognition (Psychology)
Pharmacology
Ligands
Injections

Keywords

  • Antipsychotic
  • Cholinergic
  • Cognition
  • Nicotinic receptor
  • Schizophrenia

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine. / Poddar, Indrani; Callahan, Patrick Michael; Hernandez, Caterina M.; Yang, Xiangkun; Bartlett, Michael G.; Terry, Alvin V.

In: Biochemical Pharmacology, Vol. 151, 01.05.2018, p. 180-187.

Research output: Contribution to journalArticle

Poddar, Indrani ; Callahan, Patrick Michael ; Hernandez, Caterina M. ; Yang, Xiangkun ; Bartlett, Michael G. ; Terry, Alvin V. / Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine. In: Biochemical Pharmacology. 2018 ; Vol. 151. pp. 180-187.
@article{6af9f86a9115472c86f105605eb3ba0c,
title = "Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine",
abstract = "While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20 years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5 mg/kg/day) or quetiapine (25.0 mg/kg/day) for 30 or 90 days and then an acute injection of vehicle or tropisetron (3.0 mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90 days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90 days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.",
keywords = "Antipsychotic, Cholinergic, Cognition, Nicotinic receptor, Schizophrenia",
author = "Indrani Poddar and Callahan, {Patrick Michael} and Hernandez, {Caterina M.} and Xiangkun Yang and Bartlett, {Michael G.} and Terry, {Alvin V}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bcp.2017.11.017",
language = "English (US)",
volume = "151",
pages = "180--187",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Tropisetron enhances recognition memory in rats chronically treated with risperidone or quetiapine

AU - Poddar, Indrani

AU - Callahan, Patrick Michael

AU - Hernandez, Caterina M.

AU - Yang, Xiangkun

AU - Bartlett, Michael G.

AU - Terry, Alvin V

PY - 2018/5/1

Y1 - 2018/5/1

N2 - While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20 years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5 mg/kg/day) or quetiapine (25.0 mg/kg/day) for 30 or 90 days and then an acute injection of vehicle or tropisetron (3.0 mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90 days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90 days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.

AB - While impairments of cognition in schizophrenia have the greatest impact on long-term functional outcome, the currently prescribed treatments, antipsychotic drugs (APDs), do not effectively improve cognition. Moreover, while more than 20 years have been devoted to the development of new drugs to treat cognitive deficits in schizophrenia, none have been approved to date. One area that has not been given proper attention at the preclinical or clinical stage of drug development is the chronic medication history of the test subject. Hence, very little is known about how chronic treatment with drugs that affect multiple receptors like APDs influence the response to a potential pro-cognitive agent. Therefore, the purpose of this study was to evaluate the α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonist, tropisetron in rats chronically treated with APDs with distinct pharmacological profiles. Rats were treated orally with either risperidone (2.5 mg/kg/day) or quetiapine (25.0 mg/kg/day) for 30 or 90 days and then an acute injection of vehicle or tropisetron (3.0 mg/kg) was administered before training in a novel object recognition (NOR) task. After a 48 h delay (when recollection of the familiar object was impaired in vehicle-treated animals) neither 30 nor 90 days of risperidone or quetiapine treatment improved NOR performance. In contrast, tropisetron markedly improved NOR performance in rats treated with either APD for 30 or 90 days. These animal data reinforce the argument that two commonly prescribed APDs are not pro-cognitive agents and that α7 nAChR ligands like tropisetron have potential as adjunctive treatments in schizophrenia.

KW - Antipsychotic

KW - Cholinergic

KW - Cognition

KW - Nicotinic receptor

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85037620071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037620071&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2017.11.017

DO - 10.1016/j.bcp.2017.11.017

M3 - Article

C2 - 29175423

AN - SCOPUS:85037620071

VL - 151

SP - 180

EP - 187

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -